# LTZ-301

Source: https://onco.cc/drugs/ltz-301/  
OnCo record `ltz-301` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LTZ-301 is an experimental bispecific antibody from LTZ Therapeutics, in phase 1 trials for relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma and other cancers.

## Summary

LTZ-301 is a bispecific antibody (myeloid cell engager) from LTZ Therapeutics. A bispecific myeloid engager that redirects monocytes and macrophages to CD79b-positive B cells and depletes them by Fc-receptor-independent antibody-dependent cellular phagocytosis. Its furthest stage is phase 1, for relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma. ClinicalTrials.gov registers it in one study linked below. FDA IND cleared February 2025; phase 1 recruiting (NCT07121946). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: LTZ-301
- Modality: Bispecific antibody (myeloid cell engager)
- Mechanism: A bispecific myeloid engager that redirects monocytes and macrophages to CD79b-positive B cells and depletes them by Fc-receptor-independent antibody-dependent cellular phagocytosis.

## Sources

- LTZ Therapeutics: ltztherapeutics.com: https://www.ltztherapeutics.com/html/news/118.html
- LTZ Therapeutics: ltztherapeutics.com: https://www.ltztherapeutics.com/pipeline/index.html
- ClinicalTrials.gov: trials of LTZ-301: https://clinicaltrials.gov/search?intr=LTZ-301

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [CD79b](https://onco.cc/targets/cd79b/)
- companies: [LTZ Therapeutics](https://onco.cc/companies/ltz-therapeutics/)
- trials: [This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma](https://onco.cc/trials/nct07121946/)

---
JSON: https://onco.cc/api/v1/entities/ltz-301.json